• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
Home
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise

David Brennan

Alexion
Pharma

How Alexion's asking AZ to up its offer almost cost it a deal

A surprising tax scrutiny almost derailed deal talks between Alexion and AstraZeneca ahead of their proposed $39 billion merger.
Angus Liu Apr 14, 2021 11:38am
Soliris

Alexion says top brass pressured staff to pad Soliris sales

Jan 5, 2017 9:26am
Soliris

Emergency Alexion chief Brennan says he's '120% committed'

Dec 13, 2016 11:15am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy